TCCL Archive
Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival
TCCL Archive
Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis
TCCL Archive
Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL
TCCL Archive
Biomarker May Predict Prostate Cancer Metastases
TCCL Archive
Individualized Cancer Vaccines Show 90% Survival at 6 Months
TCCL Archive
Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial
TCCL Archive
Two Phase II Studies of Ibrutinib Deliver High Response Rates
TCCL Archive
NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent
TCCL Archive
Study: BRCA2-Negative Women Could Still Have High Risk
TCCL Archive
Velcade Addition Can Improve Graft-Versus-Host Outcomes
TCCL Archive
NCI CTEP Approved Trials For the Month of December
TCCL Archive
FDA Expands Nexavar Indication To Include Thyroid Cancer
Trending Stories
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- An opportunity for Trump: Position U.S. cancer science to lead the world
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI
- Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges